S.M.A.R.T. and S.M.A.R.T. CONTROL Vascular Stent Systems; S.M.A.R.T. RADIANZ Vascular Stent System
Cordis US Corporation · Decision date Oct 15, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision (OK30) dated 2026-10-15 for P120002/S036, a supplement to the S.M.A.R.T. and S.M.A.R.T. CONTROL Vascular Stent Systems and the S.M.A.R.T. RADIANZ Vascular Stent System, submitted by Cordis US Corporation. The supplement type is a 30-Day Notice, and the recorded reason is a process change involving a manufacturer, sterilizer, packager or supplier.
The recorded statement covers approval for an alternate supplier of a Bismuth Sub Carbonate Blend used in the catheter outer member. This is a supply-chain change to one catheter component, not a new approval of the stent systems as a whole. The source does not describe the blend's function, the prior supplier, or any testing submitted, so the basis for the decision and any labeling effect remain unknown.
The device category is a superficial femoral artery stent (product code NIP) in the cardiovascular specialty. The record does not state clinical indications, patient-selection criteria or performance data, and none should be inferred from this supplement.
FDA approval order statement
approval for an alternate supplier of a Bismuth Sub Carbonate Blend used in the catheter outer member
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120002/S036
- Regulatory pathway
- PMA supplement
- Applicant
- Cordis US Corporation
- Product code
- NIP
- Decision code
- OK30
- Decision date
- Oct 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Cordis US Corporation
- Product code
- NIP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P120002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120002 · Original PMA
SMA RT CONTROL AND SMART VASCULAR STENT SYSTEMS
P120002/S036 received
Application receipt date recorded by FDA.
P120002/S036 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P120002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cordis US Corporation | PMA approval | Nov 7, 2012 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cordis US Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 14201 NW 60th Ave., Miami Lakes, FL, 33014
Sources and methodology
- Original FDA record: P120002/S036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



